Acquisition adds ABS-011, an investigational Phase 2b gallium-68-labeled PET radiodiagnostic tracer targeting HER2

此次收购增加了ABS-011，这是一种针对HER2的、处于2b期临床试验阶段的镓-68标记PET放射性诊断示踪剂

Transaction strengthens Curium radiodiagnostic capabilities and oncology footprint, including in breast and gastric cancers

该交易增强了Curium在放射性诊断领域的能力及其在肿瘤学领域的布局，包括乳腺癌和胃癌领域。

BOSTON and LIEGE, Belgium, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Curium™ a leading global radiopharmaceutical company, announced that it has completed the acquisition of Abscint SA, a Belgian clinical-stage radiopharmaceutical company developing innovative diagnostic imaging agents for oncology.

比利时波士顿和列日，2026年8月10日（环球电讯社）——全球领先的放射性药物公司Curium™宣布，已完成对比利时临床阶段放射性药物公司Abscint SA的收购。该公司致力于开发用于肿瘤学的创新诊断成像剂。

Through the transaction, Curium has acquired the global rights to develop, manufacture and commercialize ABS-011, an investigational gallium-68-labeled positron emission tomography (PET) radiodiagnostic tracer designed to target human epidermal growth factor receptor 2 (HER2). HER2 is an important biological target in several cancers, including breast and gastric cancers.

通过此次交易，Curium 获得了开发、生产和商业化 ABS-011 的全球权利。ABS-011 是一种在研的镓-68 标记正电子发射断层扫描（PET）放射性诊断示踪剂，旨在靶向人表皮生长因子受体 2（HER2）。HER2 是包括乳腺癌和胃癌在内的多种癌症中的重要生物靶点。

By enabling whole-body, quantitative imaging of HER2 expression, ABS-011 has the potential to provide a more complete and comprehensive view of HER2 status to support more informed patient characterization and clinical assessment, subject to further clinical development and regulatory review..

通过实现HER2表达的全身定量成像，ABS-011有望提供更全面、更完整的HER2状态视图，从而支持更精准的患者特征分析和临床评估，但需经过进一步的临床开发和监管审查。

ABS-011 uses a radiolabeled single-domain antibody designed to bind HER2 rapidly while unbound tracer clears quickly from the bloodstream. This enables same-day, whole-body PET imaging of HER2 expression across multiple lesions, potentially revealing spatial heterogeneity that a single-lesion biopsy may miss and helping clinicians select a more informative lesion for biopsy..

ABS-011 采用一种放射性标记的单域抗体，旨在快速结合 HER2，同时未结合的示踪剂能迅速从血液中清除。这使得在同一天内对全身多处病灶的 HER2 表达进行 PET 成像成为可能，有望揭示单点活检可能遗漏的空间异质性，并帮助临床医生选择更具信息价值的病灶进行活检。

ABS-011 is currently being evaluated in the HERMIA trial, a multicentered Phase 2b clinical trial in Belgium (NCT 06369831). Curium plans to apply its experience in radiopharmaceutical development, manufacturing and commercialization to support the continued development of the asset.

ABS-011 目前正在 HERMIA 试验中进行评估，这是一项在比利时开展的多中心 IIb 期临床试验（NCT 06369831）。Curium 计划凭借其在放射性药物开发、生产和商业化方面的经验，支持该资产的持续开发。

Chait Tatineni, CEO Curium Biopharma, said:

Curium Biopharma 首席执行官 Chait Tatineni 表示：

“This acquisition adds a promising diagnostic asset to Curium’s oncology pipeline and builds on our commitment to advancing innovative radiopharmaceuticals for patients affected by cancer. We believe ABS-011 could help provide a more complete picture of HER2 expression across the body, with the potential to guide optimal care for patients with cancers where HER2 plays an important role.

“此次收购为Curium公司的肿瘤学产品线增添了一项前景广阔诊断资产，并进一步巩固了我们致力于推进创新放射性药物、造福癌症患者的承诺。我们认为，ABS-011有望更全面地呈现HER2在全身的表达情况，从而为HER2在其中发挥重要作用的癌症患者提供优化诊疗指导。”

Alongside the Abscint team, Curium strengthens capabilities to help advance this program toward regulatory approval and ultimately access by patients who may benefit from it.”.

Curium 与 Abscint 团队合作，增强相关能力，以推动该项目获得监管批准，并最终惠及可能从中受益的患者。

Karine Clauwaert, CEO, Abscint SA, said:

Abscint SA 首席执行官 Karine Clauwaert 表示：

“Abscint has worked to develop a differentiated approach to HER2 imaging, driven by the belief that better diagnostics can lead to better care. We are pleased that Curium will help advance ABS-011 into its next stage of development. Curium’s scale, expertise and long-standing focus on nuclear medicine make it well positioned to support the next phase of development for this important program.”.

“Abscint致力于开发一种差异化的HER2成像方法，其动力源于这样一种信念：更优质的诊断能够带来更佳的医疗护理。我们很高兴Curium将帮助推动ABS-011进入下一阶段的开发。Curium的规模、专业知识以及在核医学领域的长期专注，使其具备充分优势，能够为这一重要项目的下一阶段开发提供支持。”

About ABS-011

关于 ABS-011

ABS-011 is an investigational gallium-68-labeled PET radiodiagnostic tracer targeting HER2. It is being evaluated in a multicenter Phase 2b clinical trial in Belgium. ABS-011 has not been approved by any regulatory authority, and its safety and efficacy have not been established.

ABS-011 是一种针对 HER2 的在研镓-68 标记 PET 放射性诊断示踪剂。目前，该药物正在比利时进行一项多中心 IIb 期临床试验。ABS-011 尚未获得任何监管机构的批准，其安全性和有效性也尚未确立。

About Curium™

关于 Curium™

Curium™ is a leading global radiopharmaceutical company with proven expertise in the development, manufacturing and supply of radiopharmaceuticals that transform the way cancer is diagnosed and treated. Headquartered in Boston with offices around the world, Curium’s mission is to find new and better ways to diagnose and treat cancer..

Curium™ 是一家全球领先的放射性药物公司，在开发、生产和供应放射性药物方面拥有经证实的专业知识，这些药物正在改变癌症的诊断和治疗方式。Curium 总部位于波士顿，在全球各地设有办事处，其使命是寻找更新、更好的癌症诊断和治疗方法。

With a global footprint that extends to more than 70 countries, a skilled and dedicated team of over 3,800 employees, and more than 80 manufacturing sites globally, Curium is highly qualified to meet the significant supply and distribution of established products that underlie success in the radiopharmaceuticals market.

Curium 的业务遍及全球70多个国家，拥有超过3,800名技能娴熟、敬业奉献的员工，以及遍布全球的80多个生产基地，具备强大的实力，能够满足放射性药物市场中成熟产品的大规模供应与分销需求，从而奠定其成功基石。

Curium’s global leadership is embodied in a diverse and extensive portfolio of over 45 products that advance patient care for a wide range of cancers..

Curium 的全球领导地位体现在其多样化且广泛的产品组合中，该组合包含 45 余种产品，旨在推进多种癌症的患者护理。

Curium’s pioneering legacy in nuclear medicine is the foundation of the company’s dedication to innovation and portfolio expansion to cancer therapeutics, particularly in neuroendocrine tumors and with a late-stage pipeline exploring opportunities in prostate cancer.

居里公司在核医学领域的开创性传承，奠定了其致力于创新及将产品组合拓展至癌症治疗领域的基础，特别是在神经内分泌肿瘤方面，并拥有处于后期研发阶段的管线，以探索前列腺癌领域的机会。

To learn more, visit

了解更多，请访问

www.curiumpharma.com

www.curiumpharma.com

.

。

About ABSCINT

关于 ABSCINT

ABSCINT is a clinical-stage molecular imaging company and a spin-off from Vrije Universiteit Brussel (VUB). The company develops next-generation diagnostic tools based on radiolabelled single-domain antibodies (sdAbs), designed to provide a non-invasive, whole-body view of disease biology.ABSCINT is backed by a complementary investor consortium comprising Qbic, Noshaq, Wallonie Entreprendre (WE), UZ Brussel, Kazoku and strategic industry partner Trasis, alongside private investors including Koen Dewaele, Chair of ABSCINT’s Board of Directors.

ABSCINT 是一家处于临床阶段的分子影像公司，是布鲁塞尔自由大学（VUB）的衍生企业。该公司开发基于放射性标记单域抗体（sdAbs）的下一代诊断工具，旨在提供对疾病生物学的无创、全身性视图。ABSCINT 获得了一个互补型投资者财团的支持，该财团包括 Qbic、Noshaq、Wallonie Entreprendre（WE）、布鲁塞尔大学医院（UZ Brussel）、Kazoku 以及战略行业合作伙伴 Trasis，此外还有包括 ABSCINT 董事会主席 Koen Dewaele 在内的私人投资者。

Beyond capital, the consortium brings expertise in life sciences, diagnostics, entrepreneurship and nuclear medicine. Its members share ABSCINT’s conviction that better diagnostics are essential to select treatments more precisely and unlock the full potential of precision medicine..

除了资本之外，该联盟还带来了在生命科学、诊断学、创业精神和核医学领域的专业知识。其成员与ABSCINT持有相同的信念：更好的诊断对于更精确地选择治疗方案以及释放精准医疗的全部潜力至关重要。

Inquiries:

咨询：

Curium Group

居里集团

Camilla Campbell

卡米拉·坎贝尔

VP, Head of Global Communications

副总裁，全球传播主管

Camilla.campbell@curiumpharma.com

Camilla.campbell@curiumpharma.com